293 related articles for article (PubMed ID: 27400930)
1. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
[TBL] [Abstract][Full Text] [Related]
2. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.
McGuire JL; Gill AJ; Douglas SD; Kolson DL;
J Neurovirol; 2015 Aug; 21(4):439-48. PubMed ID: 25776526
[TBL] [Abstract][Full Text] [Related]
3. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda.
Abassi M; Morawski BM; Nakigozi G; Nakasujja N; Kong X; Meya DB; Robertson K; Gray R; Wawer MJ; Sacktor N; Boulware DR
J Neurovirol; 2017 Jun; 23(3):369-375. PubMed ID: 27995575
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
[TBL] [Abstract][Full Text] [Related]
6. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
[TBL] [Abstract][Full Text] [Related]
7. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.
Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR
J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220
[TBL] [Abstract][Full Text] [Related]
8. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
[TBL] [Abstract][Full Text] [Related]
10. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.
Pérez-Santiago J; Schrier RD; de Oliveira MF; Gianella S; Var SR; Day TR; Ramirez-Gaona M; Suben JD; Murrell B; Massanella M; Cherner M; Smith DM; Ellis RJ; Letendre SL; Mehta SR
J Neurovirol; 2016 Apr; 22(2):191-200. PubMed ID: 26428514
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy.
Anderson AM; Easley KA; Kasher N; Franklin D; Heaton RK; Zetterberg H; Blennow K; Gisslen M; Letendre SL
J Neurovirol; 2018 Dec; 24(6):695-701. PubMed ID: 30105502
[TBL] [Abstract][Full Text] [Related]
12. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.
Edén A; Marcotte TD; Heaton RK; Nilsson S; Zetterberg H; Fuchs D; Franklin D; Price RW; Grant I; Letendre SL; Gisslén M
PLoS One; 2016; 11(6):e0157160. PubMed ID: 27295036
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
[TBL] [Abstract][Full Text] [Related]
14. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
[TBL] [Abstract][Full Text] [Related]
15. CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.
Abdulle S; Mellgren A; Brew BJ; Cinque P; Hagberg L; Price RW; Rosengren L; Gisslén M
J Neurol; 2007 Aug; 254(8):1026-32. PubMed ID: 17420923
[TBL] [Abstract][Full Text] [Related]
16. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
Jessen Krut J; Mellberg T; Price RW; Hagberg L; Fuchs D; Rosengren L; Nilsson S; Zetterberg H; Gisslén M
PLoS One; 2014; 9(2):e88591. PubMed ID: 24523921
[TBL] [Abstract][Full Text] [Related]
17. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART).
Merlini E; Iannuzzi F; Calcagno A; Bai F; Trunfio M; d'Arminio Monforte A; Bonora S; Marchetti G
J Neurovirol; 2018 Dec; 24(6):679-694. PubMed ID: 29987585
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria.
Jumare J; Sunshine S; Ahmed H; El-Kamary SS; Magder L; Hungerford L; Burdo T; Eyzaguirre LM; Umlauf A; Cherner M; Abimiku A; Charurat M; Li JZ; Blattner WA; Royal W
J Neurovirol; 2017 Jun; 23(3):474-482. PubMed ID: 28243867
[TBL] [Abstract][Full Text] [Related]
19. Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment.
Anderson AM; Lennox JL; Nguyen ML; Waldrop-Valverde D; Tyor WR; Loring DW
J Neurovirol; 2016 Dec; 22(6):816-822. PubMed ID: 27245594
[TBL] [Abstract][Full Text] [Related]
20. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
